AAN 2022 | Evaluating the long-term cognitive effects of COVID-19

Jennifer Frontera, MD, New York University Grossman School of Medicine, New York, NY, gives an overview of the neurological effects of COVID-19. Levels of established biomarkers for Alzheimer’s disease such as pTau181, NfL, GFAP and UCHL1 were higher in hospitalized patients who had neurological complications such as encephalopathy and subsequently passed away. Prof. Frontera additionally discusses the potential link between COVID-19 infection and neurodegeneration, where hypoxia may result in upregulated amyloid production and induce neurofibril tangles. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.